Sage Represents Respira Therapeutics - Opportunity to License RT234, A Late Stage Asset for Pulmonar

The Sage Group is working with Respira Therapeutics (“Respira”; http://respiratherapeutics.com/) to identify clinical and commercial development partners for its later stage, highly novel asset for treatment of serious cardiopulmonary disease.

Respira’s initial pipeline is targeting two indications with large unmet medical needs, with market potentials likely in excess of $1Bn each.

Respira is a privately funded US-based company focused on treatment of cardiopulmonary disease using a novel delivery method of its lead compound RT234 (vardenafil) to the small airways of the lungs.Respira's approach combines state-of-the-art proprietary inhaled drug formulation and dry-powder inhaler device technologies, designed to improve lung targeting and dose consistency while maximizing dose delivery to the small airways of the lungs. Respira’s initial pipeline is focused on pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) in patients with interstitial lung disease (ILD-PH).

PAH is a rare, progressive, life-threatening disease and ILD patients with PH have a worsened clinical course and higher mortality than patients with ILD alone.

Respira’s RT234 has received FDA Orphan Drug Designation for use in Pulmonary Arterial Hypertension and is in Phase 2 clinical trials for the first in class, as-needed (PRN) treatment of episodic symptoms in PAH patients.

RT234-PAH has compelling Ph2a data demonstrating hemodynamic mechanism of action and is currently recruiting patients in a Phase 2b study.RT234-PAH has a $1.3Bn addressable market in the US alone, with potential sales estimated at $500M per annum.

The second therapeutic target for RT234 is treatment of the PAH component of patients with ILD and PH (WHO Group 3.2 PH), representing an additional $1Bn market. This is a Phase 2 ready asset (RT234-ILD).